Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.8% during the 2nd quarter, Holdings Channel reports. The fund owned 7,671,157 shares of the company’s stock after purchasing an additional 419,329 shares during the period. Wellington Management Group LLP’s holdings in Teva Pharmaceutical Industries were worth $259,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $1,098,060,000. WCM Investment Management LLC lifted its position in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Schroder Investment Management Group grew its position in Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TEVA. Barclays boosted their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 21st. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.22.

Teva Pharmaceutical Industries Stock Up 0.0%

TEVA opened at $36.45 on Monday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $17.94 and a fifty-two week high of $38.37. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The company has a fifty day moving average of $34.31 and a two-hundred day moving average of $33.19. The stock has a market capitalization of $42.48 billion, a price-to-earnings ratio of 60.75, a PEG ratio of 3.91 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The business had revenue of $4.14 billion during the quarter. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.